Participated · Series E · Mar 2026

HawkEye 360 operates a constellation of satellites that detect, geolocate, and characterize radio-frequency (RF) emissions around the globe. Its proprietary signal processing and AI-driven analytics platform converts raw RF spectrum data into actionable intelligence for government and allied defense agencies. The company positions its offering as mission-critical for domain awareness and early-warning needs, enabling faster and better decision-making. HawkEye 360 is currently integrating Innovative Signal Analysis (ISA) to deepen its analytic capabilities and expand its product suite. Proceeds from recent fundraising are earmarked to strengthen the balance sheet and support this integration, as well as to continue investing in platform enhancements. Headquartered in Herndon, Virginia, the firm markets itself as a trusted partner proven by operational mission success.

Participated · Series E · Nov 2025

Ursa Major provides flight-proven propulsion solutions for hypersonics, solid rocket motors, space mobility, and launch applications. Headquartered in Berthoud, Colorado, with additive manufacturing operations in Youngstown, Ohio, the company leverages advanced production techniques and flexible architectures to serve land, air, sea, and space domains. Recent milestones include multiple successful flights of its hypersonic engines and tactical missiles, completion of tests for space-propulsion systems, and the addition of industry veterans Ronald Sugar and Gilman Louie to its board. Through the first three quarters of 2025, Ursa Major secured more than $115 million in bookings from government and commercial customers such as the U.S. Department of Defense, the U.S. Air Force Research Laboratory, Stratolaunch, and BAE Systems. The fresh capital will be used to scale manufacturing capacity, accelerate production of throttleable, storable liquid-fueled hypersonic and space-based defense solutions, and expand solid-rocket-motor output. The company positions itself as a modern alternative to legacy defense suppliers, aiming to deliver capabilities faster and at lower cost.

Participated · Series C · Dec 2021

Paradox is a conversational recruiting software platform led by founder and CEO Aaron Matos, built to give recruiters, hiring managers, and talent professionals an assistant to get work done. Its core product, Olivia, is a conversational AI assistant that automates candidate screening, interview scheduling, onboarding, and other recruiting tasks through mobile-first experiences. Olivia serves high-volume hourly and high-skilled professional roles and is used by 500+ global clients, including Unilever, Nestle, McDonald’s, CVS Health, General Motors, Lowe’s, and Shaker Recruitment Marketing. In five years the assistant has helped clients save millions of hours of manual work. Paradox acquired Traitify, a personality assessment company, in August 2021. Headquartered in Scottsdale, Arizona, the company also has offices in Chicago, Baltimore, Tel Aviv, Singapore, and Vietnam and is actively hiring across client success, sales, product, engineering, and other teams. The company’s latest financing valued it at $1.5 billion. Paradox’s core product is Olivia, a conversational AI assistant that automates recruiting and HR tasks such as screening, scheduling, onboarding, employee Q&A, collecting feedback, and hosting virtual events. Olivia engages across web, SMS, major messaging apps and voice assistants, speaks more than 100 languages, and integrates with leading HR and ATS systems like Workday, ADP, Cornerstone, iCims and others. The company serves 200+ global enterprise clients, including McDonald’s, CVS Health, and Unilever, and has grown to more than 140 employees since its 2016 founding. Paradox has received industry recognition, including awards from Human Resource Executive, Recruiting Trends & Talent Tech, the American Business Awards, and placement on Forbes’ startup employer list. The business says it will use the new funding to expedite its vision of AI as a liberating force for work, continue product and partner roadmap execution, and expand across the U.S. and internationally while remaining based in Arizona. Brighton Park Capital’s involvement is positioned to support further partnerships with HCM providers and accelerate the company’s growth. Paradox is the leading Assistive Intelligence platform transforming talent acquisition and candidate experience with its flagship AI recruiting assistant, Olivia. Olivia supports talent in more than 60 countries, communicates in over 36 languages, and assists over 150 talent-centric organizations including Compass Group, Alorica, Staples, and CVS Health. In 2018 Paradox tripled revenue, doubled its team, and tripled its client base. The company announced plans to double staffing again in 2019, hiring primarily for product, sales, and client success and opening regional offices in Dallas and Chicago to grow its U.S. footprint. Paradox says its product portfolio has broadened through client partnerships to better support candidates throughout the hiring process and their careers. The company received the Talent Solution Impact Award from Recruiting Trends & Talent Tech and was accepted into the SAP.io Foundry program.

Participated · Series E · Jun 2020

Enterome is a clinical-stage company developing first-in-class OncoMimics immunotherapies, led by lead candidate EO2463. EO2463 is an off-the-shelf immunotherapy combining four synthetic OncoMimics peptides that mimic B‑cell markers (CD20, CD22, CD37 and CD268/BAFF receptor) plus a helper peptide (UCP2) to target malignant B lymphocytes. The approach aims to provide broad target coverage to improve safety and maximize efficacy while reducing antigen-escape driven resistance. Enterome is expanding and finalizing its Phase 1/2 SIDNEY clinical trial and preparing EO2463 for a registrational program, including a planned pivotal Phase 3 for the “watch-and-wait” iNHL population. The company has held positive interactions with regulators (FDA Type C meeting and EMA Scientific Advice) that outline a clear path to marketing authorization in watch-and-wait iNHL. New and prior clinical data (including ASCO 2024 and upcoming ICML presentation) support EO2463’s activity as monotherapy and in combination and suggest biomarker-driven identification of likely responders. Enterome leverages its understanding of the gut microbiome–immune interaction to discover and develop small molecules, proteins and peptide therapeutics for cancer, autoimmune, inflammatory and metabolic diseases. Its pipeline includes cancer immunotherapies (EO2401, EO2463), EndoMimics biologics (EM101) for inflammatory diseases, and EB8018 (sibofimloc/TAK-018), an oral FimH blocker advancing in Crohn’s disease trials. EO2401 was expected to enter Phase 1/2 trials in glioblastoma and adrenal malignancies in mid-2020, while EO2463 is being prepared as a clinical candidate for B‑cell malignancies. EB8018 is partnered globally with Takeda, with Enterome retaining a significant profit share in the US. The company has operations in Paris and Boston and is led by CEO Pierre Belichard. Enterome recently closed a €46.3M financing and drew the first tranche from a previously agreed European Investment Bank loan facility to support clinical development. Enterome is a clinical-stage biotech pioneering microbiome-derived pharmaceuticals and diagnostics targeting inflammatory bowel diseases and cancer. Its lead programs are EB8018, an oral gut‑restricted FimH blocker for Crohn’s disease, and EO2315, an immuno‑oncology candidate derived from bacterial antigens. EB8018 completed a Phase 1 trial in 2017 showing safety and minimal blood absorption and is advancing to Phase 2; EO2315 has produced strong immune responses and tumor cell‑killing ex vivo and controlled tumor growth in vivo and is entering a Phase 1b study in glioblastoma. The company is also developing the next generation of its proprietary metagenomics drug discovery platform to expand therapeutic target discovery. Enterome has established partnerships with pharmaceutical companies (including Johnson & Johnson/Janssen, Takeda, Abbvie and Bristol‑Myers Squibb) and a 50/50 joint venture with Nestlé Health Science for microbiome diagnostics. The company was founded in 2012 in Paris. Enterome Bioscience SA, based in Paris and Boston, pioneers pharmaceuticals and diagnostics derived from the gut microbiome. Its lead therapeutic candidate is EB 8018, a novel small-molecule FimH antagonist licensed from Vertex that targets Adherent Invasive Escherichia coli (AIEC) proliferation. EB 8018 is being developed as a potential treatment for inflammatory bowel diseases and acts by preventing AIEC adhesion to the gut wall to help restore a dysbiotic microbiome. The company also develops microbiome-based diagnostics for IBD and other microbiome-related diseases and seeks partnerships with diagnostic and pharmaceutical companies. Enterome intends to advance therapeutic programs in immuno-oncology alongside its diagnostics and gut-focused therapies. The company will use the recent financing to support moving EB 8018 into first clinical studies in 2016. Enterome Bioscience develops disease management solutions and diagnostic products grounded in gut microbiome science. The company is building diagnostic tools to support patient stratification, personalized therapies and the clinical development of new drugs. Target indications include microbiome-related diseases such as inflammatory bowel diseases and metabolic diseases like diabetes and obesity. Enterome intends to use newly raised funds for R&D and business development activities. Founded in 2012 and led by CEO Pierre Belichard, the company is based in Paris, France. To date it has raised a total of €17.5m.

Led · Equity · Dec 2016

AnaBios is a preclinical contract research organization focused on translational research that measures drug activity directly in human tissue. The company primarily targets areas of high unmet medical need, including cardiac disease, lung disease, CNS disorders, pain, and itch. As a CRO it maintains an extensive network of hospitals and transplant centers to obtain ethically consented human tissue samples for ex vivo analysis. AnaBios announced a financing with Ampersand Capital Partners and said the funds will be used to strategically expand the business and grow capabilities across therapeutic areas. Management expects the expanded capabilities and global reach to help catalyze a larger number of successful clinical trials by improving translational models for candidate molecules. The company is based in San Diego, California. AnaBios is a San Diego–based biotechnology company that advances drug development through its proprietary Phase X technology. The company focuses on therapeutic areas with major unmet need, including pain, cardiac disease and neurodegenerative diseases. Its technology can generate human-relevant preclinical data with the potential to assess drug safety and reduce clinical-stage failures. AnaBios offers drug discovery services to major pharmaceutical companies in the USA, Europe, Japan and Korea while also conducting its own drug discovery in pain and heart disease. The company is led by CEO Andre Ghetti, Ph.D., and intends to use new funding to expand contract research capabilities and accelerate its internal drug programs. AnaBios is a contract research organization based in San Diego that deploys assays and develops databases to assess drug efficacy and safety. Its platform is designed to provide relevant data in advance of clinical trials, enabling better decision making on compound selection, dosing, and risk mitigation. The company will use its assays and databases to inform preclinical-to-clinical decision processes for drug developers. AnaBios is led by CEO and Chairman Dr. Jack A. Reynolds. Financially, the company has begun Series A fundraising and intends to raise up to $2 million. It plans to use proceeds to fund a new laboratory facility in San Diego.